Drug Profile
BIL 226
Alternative Names: BIL 226XXLatest Information Update: 21 Aug 1997
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-inflammatories; Antiasthmatics; Small molecules
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation